Wave Life Sciences (WVE) Other Non Operating Income (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Other Non Operating Income came in at -$275000.0 in Q2 2026, down 235.37% YoY from $203153.2 in Q2 2025, and down 243.75% on a QoQ basis from -$80000.0 in Q1 2026.
Analysis
Wave Life Sciences (WVE) Other Non Operating Income (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Other Non Operating Income data on file, last reported at -$275000.0 in Q2 2026.
- Quarterly Other Non Operating Income fell 235.37% year-over-year to -$275000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $203000.0 (down 92.89% YoY) and the FY2025 annual result came in at $527000.0, down 83.69% from the prior year.
- Other Non Operating Income eased to -$275000.0 in Q2 2026, from -$80000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $2.5 million in Q4 2024 to a low of -$701000.0 in Q3 2022.
- A 5-year average of $293833.3 and a median of $202500.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2024 — Other Non Operating Income soared 337.8% — and 2025, when it plunged 355.56%.
- Tracing WVE's Other Non Operating Income over 5 years: stood at -$290000.0 in 2022, then soared by 300.69% to $582000.0 in 2023, then surged by 337.8% to $2.5 million in 2024, then tumbled by 90.82% to $234000.0 in 2025, then plunged by 217.52% to -$275000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$275000.0 (Q2 2026), -$80000.0 (Q1 2026), and $234000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Wave Life Sciences | 987.40 Mn | 619.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -275,000.00 |
| Mar 31, 2026 | -80,000.00 |
| Dec 31, 2025 | 234,000.00 |
| Sep 30, 2025 | 324,000.00 |
| Jun 30, 2025 | -82,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Dec 31, 2024 | 2.55 Mn |
| Sep 30, 2024 | 337,000.00 |
| Jun 30, 2024 | -18,000.00 |
| Mar 31, 2024 | 365,000.00 |
| Dec 31, 2023 | 582,000.00 |
| Sep 30, 2023 | 171,000.00 |
| Jun 30, 2023 | 118,000.00 |
| Mar 31, 2023 | 1.01 Mn |
| Dec 31, 2022 | -290,000.00 |
| Sep 30, 2022 | -701,000.00 |
| Jun 30, 2022 | 744,000.00 |
| Mar 31, 2022 | 254,000.00 |
| Dec 31, 2021 | 1.12 Mn |
| Sep 30, 2021 | 1.37 Mn |